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Abstract: Multiple sclerosis (MS) is the prototypical inflammatory demyelinating disorder 
of the central nervous system (CNS). Although many advances have been made in the 
comprehension of its pathogenesis, the etiology is still unknown. The complexity of MS 
reflects in the extreme variability of the clinical manifestations and clinical course both 
between and within patients, in addition to immunopathological mechanisms and response 
to treatment. Several prognostic factors have been suggested in large scale studies, but 
predictions in individual cases are difficult to make. Cerebrospinal fluid (CSF) biomarkers, 
such as 14-3-3, tau, and cystatin C are promising sources of prognostic information with a 
good potential of quantitative measure, sensitivity, and reliability. However, none has 
shown sufficient reproducibility to be applied in clinical practice. Here we review the 
current literature addressing the above mentioned biomarkers as MS severity predictors at 
an early stage. 
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1. Introduction 
Multiple sclerosis (MS) is the most common chronic demyelinating disorder of the central nervous 
system (CNS). Pathogenesis is characterized by a complex interplay between genetic, autoimmune and 
environmental factors, but etiology is unknown. The biological complexity of MS is paralleled by the 
extreme variability of the clinical picture. Although 10–20% of patients have a progressive disease 
from onset (primary progressive MS), the typical clinical course is relapsing-remitting. In these 
patients the initial event of acute or subacute neurological disturbance is indicated as clinically isolated 
syndrome (CIS), although not all CIS cases necessarily convert to MS. Indeed, the natural history of 
CIS and early MS is highly variable and unpredictable at the individual level. When patients are 
diagnosed with a CIS, clinicians have to deal with many questions and challenges regarding 
differential diagnosis, the likelihood of conversion to MS, and treatment decisions. Typical findings on 
brain magnetic resonance imaging (MRI), oligoclonal bands in the cerebrospinal fluid (CSF), and/or 
evoked potentials suggestive of demyelination are associated with an increased risk of conversion to 
MS. Even in patients with early MS, many questions remain open regarding the likelihood of future 
relapses and disability. In some cases disease-modifying treatments might prevent the development of 
MS and disability, but in others they could be superfluous [1]. 
Studies of the clinical features and natural history of CIS and early MS use different groups of 
patients, either from observational investigations or from short-term therapeutic reports. In a natural 
history study of a group of CIS patients in London, UK, the percentage of subjects who developed 
clinically definite MS (CDMS) was 43% at 5 years, 59% at 10 years, and 68% at 14 years [2]. Notably, 
the presenting symptoms did not seem to affect the rate of conversion to definite MS. A study of  
308 patients from the Gothenburg, Sweden, database found that 45 out of 220 patients with a CIS still 
had a CIS at the 25-year follow-up [3]. Patients with efferent lesions had twice the risk of a later 
diagnosis of MS than those without efferent lesions, and the likelihood of being wheelchair-bound was 
2.8 times higher with efferent than non-efferent lesions, and 1.9 times higher with incomplete than 
complete remission of the CIS. Male gender, incomplete remission and high relapse rate in the first 5 
years of MS were predictive of subsequent severe disability. Another natural history study of 1215 
patients with MS in Lyon, France, found a longer period to the second episode with optic neuritis 
presentation than with either brainstem or spinal cord presentations [4]. Slow progression to disability 
milestones also occurred in patients with optic neuritis at presentation, in those with good recovery 
from the CIS, in those with a long period before the second relapse, and in those with few relapses in 
the first 5 years. Overall, however, the CIS characteristics had little effect on delay to the second 
episode and little, if any, effect on subsequent progression. 
The presence and number of lesions on brain MRI has an effect on the course of a CIS, with a 
higher risk of clinically definite MS in patients with an abnormal scan [5,6]. To a lesser extent, the 
number/location of baseline lesions and the rate of new lesions accrual predict the likelihood of 
developing subsequent disability in MS cases [7,8]. There is evidence that evoked potentials have a Int. J. Mol. Sci. 2011, 12                 
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prognostic value in MS. Patients with a high degree of evoked potentials abnormalities have an 
increased risk of disability progression in the subsequent follow-up period [9]. 
Studies of the immune activation in patients with CIS provide important information about 
immunological mechanisms. An abnormal B-cell response (shown by oligoclonal IgG in the CSF) is 
detected in about two-thirds of patients with CIS and increases the risk of MS [10]. There is evidence 
that CSF oligoclonal IgM predicts a more aggressive disease course in relapsing–remitting MS [11].
 
Detailed studies in patients with CIS suggest there may be systemic activation of myelin-reactive   
T cells, which secrete proinflammatory Th-1 cytokines. Interestingly, this activation has been 
associated with inflammatory activity on gadolinium-enhanced MRI [12]. 
Besides immunological markers, several CSF proteins have been studied as potential predictors of 
CIS/MS disease course. Among the multitude of biomarkers which have been tested, neurofilaments 
seem to stand out for potential prognostic value. Current evidence suggests that neurofilament heavy 
and light chain proteins (NfH and NfL, respectively) concentrations are increased in the CSF of MS 
patients compared to age-matched normal controls, although they do not reach the levels observed in 
neurodegenerative and more disruptive CNS disorders. Furthermore, CSF NfH and NfL levels seem to 
correlate with MS clinical course (higher levels in RR MS compared to CIS and in progressive 
compared to RR MS) and with disease activity (higher levels during relapses compared to remission 
phase). Finally, it has been shown that CSF NfH and NfL concentrations may correlate with disease 
severity both at the time of lumbar puncture and at subsequent follow-up time points [13–15]. 
Conversely, the presence of 14-3-3 protein has been associated with a higher risk of MS conversion 
and subsequent disability in patients with CIS [16]. Some studies have observed a correlation of CSF 
tau protein with disability in MS patients [17]. Recently, cystatin C has been proposed as a potential 
diagnostic and/or prognostic marker of CIS and MS [18–21]. 
2. Relevance of Cerebrospinal Fluid Biomarkers 
Research on patients with CIS/early MS may provide new insights into early pathological changes 
and pathogenetic mechanisms that might affect the course of the disorder. In the absence of robust 
clinical and paraclinical variables predicting the disease course in the individual MS patient, 
biomarkers are promising source of information with a good potential of quantitative measure, 
sensitivity, and reliability. Although lumbar puncture is a relatively invasive procedure, CSF is   
the ideal biologic sample to analyze in CNS disorders such as MS. Considering the complex 
pathogenesis of MS, no single CSF molecule is expected to have prognostic significance. However, 
families of biomarkers representative of specific pathogenetic pathways—particularly those related to 
axonal/neuronal damage—may correlate with irreversible neurological dysfunction and be used as 
prognostic indicators to identify patients at risk of a more aggressive disease course. Furthermore, such 
biomarkers may help in deciding treatment initiation and monitoring therapeutic efficacy. 
According to their biological role, CSF molecules of potential prognostic significance for MS may 
be classified as follows: 
-  markers of immune activation (e.g., cytokines, chemokines, antibodies, complement factors, 
adhesion molecules, etc.) 
-  markers of blood-brain barrier disruption (e.g., matrix metalloproteinases) Int. J. Mol. Sci. 2011, 12                 
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-  markers of demyelination (e.g., myelin basic protein, proteolytic enzymes, etc.) 
-  markers of axonal/neuronal damage (e.g., neurofilaments, tau protein) 
-  markers of non-specific biological pathways (e.g., protein 14-3-3, cystatin C, etc.) 
There is a striking amount of published data in the field of MS biomarkers and an 
omnicomprehensive revision of the literature on the topic is beyond the scope of the present   
review [22–24]. In consideration of the recent developments, the possible prognostic relevance, and 
the research experience of our group, here we will focus on a panel of CSF biomarkers including tau 
protein, 14-3-3 protein and cystatin C. 
3. 14-3-3 Protein 
14-3-3 protein belongs to a family of highly homologous acidic polypeptides of low Mr (30 kDa) 
encoded by distinct genes. There are seven known mammalian 14-3-3 isoforms (β, γ, ε, η ζ, σ, and θ) 
mainly existing as homo- or heterodimeric complexes, which coordinate adaptation in protein-protein 
interactions, act as activators or suppressors, and regulate the subcellular localization of proteins. 
Though ubiquitous, 14-3-3s are abundant in the human brain, where they represent about 1% of total 
cytosolic proteins [25,26]. These proteins have attracted interest because they are involved in important 
cellular processes such as signal transduction, cell division, growth, adhesion, differentiation, apoptosis, 
stress response and malignant transformation. In the human brain, 14-3-3s may function primarily in 
cell-signaling pathways or as second-messenger modifiers in neurons. Owing to their abundant 
expression, damage to CNS tissue may potentially cause leakage of 14-3-3 proteins into the CSF 
following cellular disruption. It is largely established that the ε and γ 14-3-3 isotypes are highly 
expressed in the CSF of patients with Creutzfeldt-Jacob disease (CJD), and that their detection has 
considerable diagnostic and prognostic value [27,28]. The ε and γ isoforms are also increased in the 
CSF of subjects with neurological disorders characterized by active axonal degeneration, but not in 
inflammatory and demyelinating CNS disorders. Notably, in a number of neurodegenerative disorders, 
increased CNS expression and/or tissue deposition of 14-3-3 proteins occur in the absence of 
concurrent CSF release. In Alzheimer’s disease (AD), the γ and ε isotypes are overexpressed in several 
brain regions, 14-3-3ζ is bound to neurofibrillary tangles, and 14-3-3η is a component of amyloid 
plaques [29]. However, 14-3-3s are essentially negative in the CSF of AD, with the exception of one 
study reporting a positive 14-3-3η essay in a small number of patients [30]. In neurodegenerative 
disorders with sequestration and aggregation of α-synuclein, such as Parkinson’s disease and dementia 
with Lewy bodies, 14-3-3 γ, ε, ζ, and θ isoforms are complexed with α-synuclein, but not expressed in 
the CSF [31,32]. CSF 14-3-3s have been investigated in several inflammatory/demyelinating disorders, 
with a wide range of results.  
In 1999 Satoh et al. reported the presence of 14-3-3 protein in the CSF of a patient affected by 
relapsing-remitting MS in an active stage and suggested that 14-3-3 protein might be expressed in 
neurons and glial cells and released into the CSF during acute stages of the disease [33]. Subsequently, 
Irani and Kerr observed a significant correlation between CSF 14-3-3 expression and neurological 
disability in a small group of patients with acute transverse myelitis, a condition sharing relevant 
pathogenetic features with MS, being even part of the clinical spectrum of the disorder [34]. Int. J. Mol. Sci. 2011, 12                 
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Martínez-Yélamos et al. reported that a positive CSF 14-3-3 assay at the first neurological event 
suggestive of CIS, might be a reliable, although low-sensitive, indicator of conversion to clinically 
definite MS and severe neurological disability [13,35]. 
Colucci et al. suggested that the detection of 14-3-3s in the CSF could be a predictor of the severity 
of the disease and also a useful marker to identify MS patients at high risk of developing severe 
disability [36]. Bartosik-Psujek and co-workers found that the presence of 14-3-3 and increased tau 
protein levels in the CSF of MS patients positively correlated with the IgG index and this association 
was present in both relapsing remitting MS (RRMS) and progressive MS patients [37]. These findings 
favor the hypothesis that inflammation may induce 14-3-3 and tau proteins release in the CSF of MS 
patients. On the contrary, our group found a positive 14-3-3 assay coupled with normal tau protein 
level in the CSF of most MS/CIS cases, including patients with inactive disease and with a long  
time-interval from acute attack to CSF collection. Presence of 14-3-3 did not correlate with clinical 
outcomes and was independent of CSF oligoclonal bands and IgG index status. In addition, 14-3-3 
protein isoforms expressed in MS/CIS patients (predominantly β and ζ) are substantially different from 
isoforms expressed in patients with CJD and ALS (predominantly γ and ε), which are characterized by 
prominent neuronal death [20,38]. This observation together with the 14-3-3/tau dissociation in the 
CSF (a pattern characterized by presence of 14-3-3 protein and normal tau levels) challenge the 
hypothesis that 14-3-3 is a marker of neuronal/axonal loss in MS. To date, the association between  
14-3-3 and poor clinical outcome is not established, due to conflicting results across studies, and, on 
the other hand, CSF 14-3-3 expression is not constantly correlated to IgG index increase and 
oligoclonal bands positivity, thus suggesting that 14-3-3 may be not a marker of humoral   
immunity activation.  
In vitro studies have shown that 14-3-3 protein interacts with vimentin and glial fibrillary acidic 
protein in cultured human reactive astrocytes derived from MS demyelinating lesions, and that 
astrocytes and oligodendrocytes, at the site of demyelinating lesions, show increased immunoreactivity 
for 14-3-3, suggesting that these cells might be the source of 14-3-3 in the CSF of MS patients [39,40]. 
Taken together, the 14-3-3 assay coupled with the characterization of 14-3-3 isotypes in the CSF of 
MS patients may provide valuable information on ongoing pathological processes, including 
demyelination, astrocytosis and neurodegeneration, thus providing support to therapeutic options.  
4. Tau Protein 
Tau is a microtubule-binding phosphoprotein, which plays an important role in axonal locomotion 
and intraneuronal transport. Tau proteins include six isoforms, with Mr ranging 45 to 65 kDa, differing 
for the presence of either three or four repeats in the carboxy-terminal region of the molecule and the 
presence of one or two inserts in the amino-terminal domain [41]. 
In normal conditions, the CSF expresses low levels of tau protein (up to 250–500 pg/mL), while tau 
concentration is elevated in neurological disorders characterized by ongoing neuronal and axonal 
degeneration, such as CJD, stroke, and encephalitis. In AD and other tauopathies, hyperphosphorylated 
tau accumulates within the neurofibrillary tangles, and is released in the CSF, representing a valuable 
diagnostic and prognostic indicator of cognitive dysfunction [42–44]. Int. J. Mol. Sci. 2011, 12                 
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Contrasting results have appeared in the literature with regard to the significance of CSF tau in MS. 
Kapaki et al. reported increased CSF tau concentrations in 36 patients with MS compared with 29  
non-matched controls (controls were 28 years older than MS patients). Increased CSF tau concentration 
was mainly driven by the 11 patients with secondary progressive and the 10 patients with primary 
progressive subtypes of MS, while the levels found in the 15 patients with relapsing-remitting subtype 
were similar to controls [45]. 
Another study found increased CSF tau levels in MS as compared to controls. The authors concluded 
that the increase of tau protein may reflect axonal injury in MS patients [46]. Martinez-Yelamos and 
coworkers described a group of early relapsing-remitting MS patients in which increased CSF tau was 
predictive of poor short-term outcome [14]. However, these findings are in contrast with those reported 
by Jimenez-Jimenez et al. and by Fiorini et al. who did not find significant differences between the 
CSF tau levels of controls and patients with MS [20,47]. These data suggest that tau protein 
concentration in the CSF is frequently normal in unselected MS cases, and that increased tau 
expression may be a marker of primary and secondary progressive forms of the disorder. 
5. Cystatin C 
Cystatin C is a protease inhibitor highly expressed by choroidal
 and leptomeningeal cells and 
localized
 in glial and neuronal cells. Cystatin C counteracts the action
 of cathepsins, a family of 
lysosomal proteins released by activated
 microglia/macrophages, and it is thought to have a major role
 
in modulating immune cell activation and inflammation-driven cell death [48]. Cystatin C has been 
found to be downregulated
 in the CSF of a number of inflammatory conditions affecting the central 
nervous system and the peripheral nervous system [18,49]. 
There is increasing evidence of a possible role of cystatin C in the pathogenesis of MS. CSF levels 
of cystatin C may mirror the extent of inflammation in early disease stages, a factor which is known to 
influence the extent of later neurodegeneration and axonal loss. In an animal model of CNS 
demyelination, Ma et al. showed an increased expression of cathepsin B and cystatin C in white matter 
astrocytes and microglia [50]. These authors suggested that during active stages of demyelination, 
microglia and macrophages produce cathepsins while astrocytes release their powerful inhibitor, 
cystatin C. After myelin disruption, myelin debris must be cleared by activated microglia and 
macrophages before the naked axons can be effectively remyelinated. The dominance of cathepsins 
over cystatin C levels may result in disregulation of cathepsins activity at later stages of demyelination, 
causing impairment of remyelination [50]. Decreased levels of cystatin C, coupled with increased 
activity of cathepsin B, were found by Nagai and coworkers in the CSF of MS patients on relapse [18]. 
In contrast, our group reported a significant increase of CSF cystatin C concentration in patients with 
CIS and MS compared to controls [20]. Recently, we explored the possible significance of CSF 
cystatin C in a study of the prognostic factors in 53 patients with first-episode acute myelitis (AM). 
Information regarding demographics, clinical status, laboratory work-up, spine and brain MRI, and 
electrophysiological assessment was collected, and tau, 14-3-3 protein and cystatin C levels were 
assessed de novo in stored CSF samples. The prognostic value of all variables was analyzed for the 
following outcomes: recovery from initial event, symptoms recurrence, conversion to MS, and 
disability level at last follow-up visit (median follow-up of 6.2 years). Six patients remained Int. J. Mol. Sci. 2011, 12                 
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monophasic, 5 developed recurrent myelitis, and 42 (79%) converted to MS. Sensory level absence, no 
sphincter involvement, abnormal brain MRI, spinal cord lesions shorter than 3 vertebral segments, and 
abnormal somatosensory evoked potentials predicted MS conversion. Forty-seven percent of patients 
with pyramidal dysfunction at onset and 40% of patients with relapses during follow-up had significant 
disability at last visit compared to 10% of patients without pyramidal manifestations and none of the 
patients without exacerbations. Tau and 14-3-3 proteins were not significantly associated with any of 
the outcomes, while in the subgroup of patients with exacerbations there was a significant correlation 
between CSF cystatin C levels and the degree of neurological disability at last visit [38]. The research 
was then extended to 39 patients with any first-episode of neurological disturbance compatible with 
the onset of MS, or CIS, such as optic neuritis, brainstem/cerebellar syndromes, and hemispheric 
syndromes, in addition to acute myelitis. At CIS presentation the spinal cord was clinically involved in 
25 patients, the brain stem/cerebellum in 12, the optic nerve in 4, the cerebral hemisphere in 3, while  
5 patients had a multifocal CIS. After a mean follow-up of 6.8 ± 3.4 years, 7 patients did not have 
further symptoms or dissemination of MRI lesions in time, whereas 32 converted to MS. Pyramidal 
system involvement at onset and moderate to severe neurological impairment at nadir were associated 
with incomplete CIS recovery. Somatosensory and motor evoked potentials suggestive of 
demyelination at CIS onset, and the occurrence of at least one relapse every 2 years during follow-up 
were associated with a higher risk of significant disability at last visit in patients who developed MS. 
Interestingly, CSF cystatin C concentration was significantly higher in patients who converted to MS 
compared to those who remained CIS. In addition, CSF cystatin C levels were correlated to the 
expanded disability status scale (EDSS) score at the end of follow-up in patients who initially had a 
CIS with spinal cord involvement [51]. 
6. Conclusions 
Biomarkers are promising tools for prognostic predictions in MS. Ideally, reliable prognostic 
studies of biomarkers should fulfill some key methodological requirements, particularly: (1) prospective 
design; (2) sufficient follow-up; (3) adequate biomarker and outcome measurement; (4) clinical 
significance of the biomarker (i.e., good correlation and consistency with relevant clinical outcomes); 
(5) reproducibility. Currently, no biomarker study has simultaneously shown such characteristics. 
In the present review, we summarize the potential diagnostic and prognostic significance of three 
CSF proteins in patients with CIS/early MS: (1) 14-3-3 protein, showing upregulation of distinct 
isoforms, which deserve further investigation to elucidate a possible prognostic significance; (2) tau 
protein, which is helpful in distinguishing demyelinating disorders from diseases characterized by 
prominent axonal loss; (3) cystatin C, a marker changing its CSF expression in accordance with 
disease stage and progression. In proposing this panel of biomarkers, we are further comforted by the 
long follow-up, over time periods of up to 10 years, long after the disease presentation. In addition, our 
strategy to explore CSF samples, collected well after the acute episodes, is at variance with most 
studies, which explore biomarkers during acute relapses and, therefore, are characterized by a 
prevalence of inflammatory proteins.  
Among explored candidates, cystatin C may have a major role in the pathogenesis of MS, and could 
be used as a potential source of prognostic information. In particular, high cystatin C concentrations in Int. J. Mol. Sci. 2011, 12                 
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the CSF may identify MS patients with an unfavorable clinical course of the disease. Further data in 
this area of research may provide new insights into the pathogenesis of irreversible neurological 
disability in MS. 
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